Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is poised for long-term success due to its strong pipeline and commercial execution with its groundbreaking ImmTAX platform. The company's main product, KIMMTRAK, is already achieving significant sales and market penetration in the treatment of mUM, and its other drug candidates show promising potential in treating various oncology, infectious, and autoimmune diseases. The recent data presented by the company at various healthcare conferences further solidifies the efficacy of KIMMTRAK and its potential for continued success. These factors, paired with the company's strong financials and continued growth, make it a promising investment opportunity.

Bears say

Immunocore Holdings is a commercial-stage biotechnology company with a diverse pipeline of drug candidates in multiple therapeutic areas. However, their main product, KIMMTRAK, is the only product generating revenue and has limited potential in treating a specific type of cancer. With no guarantee of success for their other early-stage programs, regulatory and clinical risks, and a high potential for dilution, the company may struggle to achieve their ambitious $75 price target. Additionally, their use of varying exchange rates makes their financials appear inconsistent and unreliable.

Immunocore Holdings (IMCR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 8 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.